

1 **Genetic study of intrahepatic cholestasis of pregnancy in**
2 **101,023 Chinese women unveils East Asian-specific etiology**
3 **linked to historic HBV infection**

4 Yanhong Liu^{1*}, Yuandan Wei^{1,2*}, Xiaohang Chen^{3*}, Shujia Huang^{4*}, Yuqin Gu¹, Zijing
5 Yang^{1,3}, Liang Hu³, Xinxin Guo¹, Hao Zheng¹, Mingxi Huang⁴, Shangliang Chen⁵,
6 Tiantian Xiao⁶, Yang Zhang¹, Guo-Bo Chen⁷, Likuan Xiong^{2,8}, Xiu Qiu^{4#}, Fengxiang
7 Wei^{3,9#}, Jianxin Zhen^{2#}, Siyang Liu^{1#}

8 1. School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen,
9 Guangdong 518107, China

10 2. Central Laboratory, Shenzhen Baoan Women's and Children's Hospital,
11 Shenzhen, Guangdong 518102, China

12 3. The Genetics Laboratory, Longgang District Maternity & Child Healthcare
13 Hospital of Shenzhen City, Shenzhen, Guangdong, 518172, China

14 4. Division of Birth Cohort Study, Guangzhou Women and Children's Medical
15 Center, Guangzhou Medical University, Guangzhou, 510623, China

16 5. Department of transfusion, Shenzhen Baoan Women's and Children's Hospital,
17 Shenzhen, Guangdong 518102, China

18 6. Xiangya School of Medicine, Central South University, Changsha, Hunan
19 410078, China

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 7. Center for Productive Medicine, Department of Genetic and Genomic
21 Medicine, Clinical Research Institute, Zhejiang Provincial People’s Hospital,
22 People’s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang,
23 China

24 8. Shenzhen Key Laboratory of Birth Defects Research, Shenzhen, Guangdong
25 518102, China

26 9. Longgang Maternity and Child Institute of Shantou University Medical
27 College, Shenzhen, Guangdong, 518172, China

28

29 *: Those authors contribute equally as co-first authors

30 #: Correspondence can be addressed to

31 Siyang Liu liusy99@mail.sysu.edu.cn

32 Jianxin Zhen jxzhen@qq.com

33 Fengxiang Wei haowei727499@163.com

34 Xiu Qiu xiu.qiu@bigcs.org

35

36 **Data availability**

37 GWAS summary statistics for TBA and ICP phenotypes will be made publicly
38 available in the GWAS catalog (<https://www.ebi.ac.uk/gwas/>) upon publication.

39 **Author contribution**

40 SL, FW, JZ, and XQ conceived the study. JZ, XC, LH, YW, ZY, HZ, SC, and TX
41 collected and organized the data from the maternity testing system. YL, YG, XC, LH,
42 and XG conducted data pre-processing and preliminary analyses. YL performed all
43 statistics, GWAS, and evolutionary analysis. YL and YW performed the visualization
44 of all results. JZ, SH, MH, and XQ provided the validation data. SL, FW, JZ, XQ, YZ,
45 GBC, and LX provided professional guidance and interpretation of data. YL & SL
46 wrote the manuscript with input from all authors. All authors contributed to
47 manuscript revisions and approved the final version of the article. SL is responsible
48 for the integrity of the work as a whole.

49

50 **Competing interests**

51 All authors declare no competing financial interests.

52

53 **Financial support statement**

54 The study was supported by Shenzhen Basic Research Foundation
55 (20220818100717002), Guangdong Basic and Applied Basic Research Foundation
56 (2022B1515120080, 2020A1515110859), National Natural Science Foundation of
57 China (31900487, 82203291), and the Shenzhen Health Elite Talent Training Project.

58

59 **Abstract**

60 **Background & Aims**

61 Intrahepatic cholestasis of pregnancy (ICP) is the most common and high-risk liver
62 disorder during the critical period of human reproduction. Despite varying prevalence
63 across populations, a mechanistic understanding of this phenomenon is lacking. This
64 study delves into the genetic etiology of ICP in East Asians, drawing comparisons
65 with Europeans to comprehend ICP etiology in the context of genetic background and
66 evolution.

67 **Methods**

68 We conducted the hitherto largest-scale genome-wide association studies (GWAS) on
69 total bile acid concentration (TBA) and ICP among 101,023 Chinese pregnancies. The
70 findings were subsequently replicated in two cohorts and compared with European
71 populations. Additionally, phenome-wide association and spatio-temporal evolution
72 analyses were employed to understand the function and explore evolutionary pattern
73 of sites associated with ICP.

74 **Results**

75 We identified eight TBA and five ICP loci, including ten novel loci. Notably, we
76 found an East-Asian-specific genetic locus at 14q24.1, contributing to a 6.41 $\mu\text{mol/L}$
77 increase in TBA and a 15.23-fold higher risk of ICP per risk allele (95% *CI*: 15.10 to

78 15.36, $P = 9.23 \times 10^{-375}$). Phenome-wide association studies and spatial-temporal
79 evolution analyses revealed that the 14q24.1 ICP risk locus exhibits resistance to
80 hepatitis B infection and has become prevalent only within the last 3,000 years in East
81 and Southeast Asia.

82 **Conclusions**

83 Our investigations have unraveled a distinct etiology of ICP between Europeans and
84 East Asians, and has linked ICP etiology in East Asians to a historical HBV epidemic
85 in East and Southeast Asia within the last 3,000 years. These findings lay the
86 groundwork for an improved biological understanding of ICP pathophysiology.
87 Further exploration and utilization of these variations hold the potential for more
88 precise detection, assessment, and treatment of ICP.

89

90 **Lay summary**

91 Intrahepatic cholestasis of pregnancy (ICP) is a prevalent and high-risk liver disorder
92 that occurs during pregnancy, a critical period in human reproduction. It affects
93 approximately 1% to 6.06% pregnancies and has been associated with severe adverse
94 outcomes such as preterm birth and stillbirth. While rare and common variants
95 associated with ICP have been identified in the European population, the genetic basis
96 of ICP in East Asian population remains uncharacterized. Here, we conducted the
97 largest-scale genome-wide association studies to date for TBA and ICP among

98 101,023 Chinese pregnant women, including 4,703 cases and 96,320 controls from
99 two hospitals in Shenzhen, China. We replicated our findings in two independent
100 Chinese cohorts and compared them with ICP genetic studies in the European
101 population. We identified eight and five genome-wide significant loci for TBA and
102 ICP, respectively, including ten novel loci. Notably, we identified an
103 East-Asian-specific genetic locus contributing to a 6.41 $\mu\text{mol/L}$ increase in TBA per
104 risk allele and a 15.23-fold higher risk of ICP. Further exploration through
105 phenome-wide association studies and spatial-temporal evolution analyses revealed
106 that the 14q24.1 ICP risk locus exhibits resistance to hepatitis B infection and has
107 become prevalent only within the last 3,000 years in East and Southeast Asia. These
108 findings suggest a historical HBV epidemic in East and Southeast Asia within 3,000
109 years may have contributed to the increased prevalence of ICP and TBA risk alleles
110 among East Asians. Our study unravels a distinct genetic etiology of ICP between
111 Europeans and East Asians. These findings lay the foundation for an improved
112 understanding of ICP pathophysiology and emphasize the need for integrating
113 population evolution into genetic medicine for personalized genomics and clinical
114 guidance.

115

116 **Highlights**

117 (1) In the most powerful genome-wide association studies on TBA and ICP in East
118 Asians to date, we identified eight and five genetic loci, respectively, of which, 7
119 and 3 were novel discoveries.

120 (2) One of the novel loci, the 14q24.1 locus, stands out as it contains unique causal
121 genetic variants specific to East-Asians. These variants demonstrate large effects,
122 contributing to an average increase of 6.41 $\mu\text{mol/L}$ in TBA per risk allele and a
123 15.23-fold higher risk of ICP.

124 (3) The risk mutations associated with ICP at the 14q24.1 exhibit resistance to
125 hepatitis B infection and has only become prevalent within the last 3000 years in
126 East and Southeast Asia.

127 **Key words:** Intrahepatic cholestasis of pregnancy; Total bile acid; Genetic etiology;
128 Evolutionary history; East Asians; 14q24.1

129

130 **Introduction**

131 Intrahepatic cholestasis of pregnancy (ICP) is the most prevalent and high-risk liver
132 disorder occurring during pregnancy, a critical phase in human reproduction¹. The
133 disease is characterized by maternal pruritus and elevated serum bile acid
134 concentrations ($\geq 10\mu\text{mol/L}$), with diagnosis typically involving assessing maternal
135 total serum bile acids (TBA) during routine pregnancy screening in the late second
136 and third trimesters². ICP has been associated with several severe adverse pregnancy
137 outcomes, including increased risks of spontaneous and iatrogenic preterm birth,
138 meconium-stained amniotic fluid, fetal asphyxia, and stillbirth^{3,4}. A large-scale
139 meta-analysis of ICP cases revealed that a TBA level of $100\mu\text{mol/L}$ is associated with
140 an elevated risk of stillbirth, with a hazard ratio [*HR*] of 30.5 [95% *CI*: 8.83–105.30],
141 compared to a TBA level below $40\mu\text{mol/L}$ ⁵. Several retrospective studies and case
142 reports underscore the unpredictability of prenatal fetal death in patients with ICP
143 after 36 weeks of pregnancy^{2,6,7}. At present, oral ursodeoxycholic acid (UDCA) is the
144 most commonly employed treatment in clinics to alleviate maternal pruritus and
145 improve liver function. However, a recent clinical randomized controlled trial
146 declared that treatment with UDCA does not reduce adverse perinatal outcomes in
147 women with ICP¹, leaving its effectiveness in enhancing perinatal outcomes and the
148 long-term health of mothers with ICP and their children inconclusive⁸.

149

150 Unraveling new treatments of ICP necessitates a profound understanding of the
151 disease's etiology. Accumulated evidence suggests the complexity of ICP etiology,
152 which is associated with genetic, endocrine, and environmental factors⁹. Familial
153 clustering of ICP strongly implies a genetic basis¹⁰. Family-based studies indicate that
154 the heterozygous state for an *MDR3* (alias *ABCB4*) gene defect likely represents a
155 genetic predisposition within families^{11,12}. A candidate gene analysis study identified
156 six SNPs in each of the *ABCB4* and *ABCB11* genes that demonstrated a significant
157 association with ICP¹³. Case-control study also showed that *ABCB4*, *ABCB11*, and
158 *ATP8B1* genes are related to intrahepatic cholestasis of pregnancy¹⁴. Case reports
159 have proposed that NTCP deficiency, encoded by *SLC10A1* gene, might be a genetic
160 factor contributing to ICP¹⁵. A recent genome-wide meta-association study involving
161 1,138 ICP cases and 153,642 controls from three European studies identified eleven
162 genes associated with ICP risk, most of which are related to hepatic functions¹⁶.

163

164 Notably, global prevalence of ICP varies substantially among different ethnicities. ICP
165 affects approximately 0.32% of pregnancies in the United States, 5.6% in the Latina
166 population in Los Angeles^{17,18}, 0.7% in the United Kingdom¹⁷, 1.5%-4% in Chile^{19,20}
167 and 1.2% to 6.06% in China²¹. However, despite its variable geographical prevalence,
168 factors influencing these differences are poorly understood. In addition, despite the
169 considerably higher prevalence of the disease among East Asians, no studies of
170 sufficient power have been conducted among the East Asian populations.

171

172 To address these gaps, we conducted the most powerful genome-wide association
173 study (GWAS) of TBA and ICP in East Asia to date, utilizing sequencing data from
174 the non-invasive prenatal testing (NIPT) of 101,023 Chinese pregnant women and
175 comprehensive phenotypic records from two hospitals in Shenzhen city in South
176 China. The discoveries were replicated in two independent Chinese datasets and
177 compared to previous findings among the European population. Intriguingly, we
178 found distinct etiology of ICP among Europeans and Asians. Among the ten novel loci
179 previously not reported in the GWAS catalog, a genetic locus in 14q24.1 present
180 exclusively among East Asians stands out, contributing to an average increase of 6.41
181 $\mu\text{mol/L}$ in TBA per risk allele and a 15.23 times higher risk of ICP in East Asians.
182 Further phenome-wide association and spatio-temporal evolutionary studies have
183 linked this ICP risk locus to a putative HBV epidemic in East and Southeast Asia
184 within the last 3000 years.

185

186 **Result**

187 **Study design and TBA phenotypic distribution**

188 The design of the study is summarized in **Abstract Figure**. In Shenzhen city, China,
189 government-sponsored Non-Invasive Prenatal Tests (NIPT) were administered as a
190 standard examination. Over the period from 2017 to 2022, we recruited 101,023
191 pregnant women during routine obstetric examinations across two Shenzhen hospitals
192 (Baoan and Longgang). Each pregnant woman underwent both a NIPT test and at
193 least one TBA test between the 13th and 42nd gestational weeks. After excluding
194 outliers, 94,360 pregnancies with normal TBA levels ($< 10\mu\text{mol/L}$) were included
195 for the GWAS of plasma TBA levels. Using the inclusion and exclusion criteria
196 detailed in the Methods section, 4,703 pregnancies were identified as ICP cases, while
197 96,320 individuals served as controls for the ICP GWAS.

198

199 **Supplementary Fig. 1** illustrates a positively skewed phenotypic distribution of TBA
200 levels, which exhibits a consistent median of $2.90\ \mu\text{mol/L}$ (Interquartile Range [IQR]:
201 [2.00, 4.20]) among normal pregnancies and a median of $14.52\ \mu\text{mol/L}$ (IQR: [11.58,
202 23.10]) among ICP cases. The distribution of TBA levels, maternal age (29.72 ± 4.47
203 years old), and gestational week (33.05 ± 8.48 weeks) are similar between the two
204 hospitals (**Supplementary Table 1**).

205

206 We employed a well-established genetic analysis pipeline developed in our previous
207 studies to analyze the NIPT data^{22,23} and conduct the GWAS for TBA level and ICP
208 across over 7 million sequence variants with minor allele frequency (MAF) greater
209 than 1% in the study cohorts. We replicated the genetic findings in two independent
210 Chinese datasets and provided meta-analysis estimates. We further conducted
211 phenome-wide colocalization analyses to examine the genetic associations across a
212 hundred pregnancy phenotypes. For the most significant and East Asian-specific
213 14q24.1 locus, we conducted spatio-temporal and natural selection evolutionary
214 analyses to explore the frequency changes of the ICP risk alleles globally and since
215 the Holocene.

216

217 **Genome-wide association study of TBA and ICP among the 101,023 pregnancies**

218 Power estimations for the meta-GWAS design indicate an 80% statistical power to
219 detect genetic associations with an effect size (β) > 0.170 and $MAF \geq 0.05$, or
220 otherwise $\beta > 0.370$ and $MAF \geq 0.01$ for TBA, and similarly for genetic associations
221 with an odds ratio (OR) > 1.140 and $MAF \geq 0.05$ as well as an $OR > 1.320$ and MAF
222 ≥ 0.01 for ICP (**Fig. S2**). The genomic inflation (λ) values for TBA and ICP
223 were 1.069 and 1.018, respectively, suggesting negligible confounding of population
224 stratification (**Fig. S3**).

225

226 In total, we identified 1,673 and 1,281 genome-wide significant variants ($P < 5 \times 10^{-8}$),
227 constituting 19 and 16 independent association signals for TBA and ICP respectively
228 (**Table S2**). These were represented by 8 independent association loci for TBA and 5
229 for ICP (**Fig. 1; Table 1; Table S3**). Among the 13 association loci, 7 and 3 were not
230 previously reported in the GWAS catalog or PhenoScanner and were identified as
231 novel loci (gene symbols in red in **Fig. 1**).

232

233 We assessed the fidelity of the association signals by comparing the effect estimates
234 between the two independent hospitals (internal replication) and with two external
235 Chinese datasets (external replication) (**Materials and Methods**). The effect
236 estimates demonstrated high consistency between the two hospitals, where 18/19
237 association signals (94.8%) or 7/8 loci (87.5%) exhibited the same beta direction and
238 surpassed Bonferroni correction significance levels for TBA in each hospital.

239 Similarly, for ICP, all 16 association signals included in the 5 loci exhibited the same
240 effect direction and significant P value after Bonferroni-correction (**Fig. S4, Table**
241 **S2-S3**). The only *GREB1* gene locus (lead SNP rs10929754-T) associated with TBA
242 did not pass the Bonferroni correction significance level in the Baoan cohort.

243 However, it consistently showed the same effect direction and achieved nominal
244 significance ($P=0.0233$). The effect estimates also demonstrated high consistency
245 between our study and the two Chinese external datasets, where all signals and loci
246 were replicated in one of the two external datasets (**Fig. S5, Table S2, Table S4**). The

247 LocusZoom regional association maps for the eight loci associated with TBA and the
248 five loci associated with ICP are presented in **Fig. S6-S7**. The above evaluations
249 suggest high fidelity of the associations identified in our study.

250

251 **The East Asian-specific at 14q24.1 locus contributes to a 15.23-fold higher risk of**
252 **ICP**

253 Seven out of the eight loci associated with TBA and three of the five loci associated
254 with ICP were not previously documented in the GWAS catalog²⁴ and PhenoScanner²⁵,
255 particularly in the current unique ICP GWAS among the European population¹⁶.

256 Genes contained within the genetic loci associated with TBA levels and ICP are
257 enriched in bile acid and bile salt transport, bile acid signaling and biosynthetic
258 processes, as well as lipid metabolism (**Table S5**). Specifically, the *ABCB11*, *ABCG5*
259 and *SLC10A1* loci associated with ICP are uniquely expressed in liver tissue²⁶ and
260 hepatocyte cells²⁷, reflecting the central role of the liver organ in the development of
261 ICP. Notably, we observed substantial discrepancies in genetic discoveries between
262 our study and the European ICP GWAS study (**Fig. S8, Table S2 and Table S5**).

263 Particularly, variants within the 14q24.1 locus, encompassing the *ERH*, *SLC39A9* and
264 *SLC10A1* genes, are absent outside East Asian populations. This includes the lead
265 SNPs rs137983251-G associated with TBA, the lead SNP rs147525203-C associated
266 with ICP and the missense variants rs2296651-A (*p.Ser267Phe*) present in *SLC10A1*
267 which is strongly associated with TBA and ICP risk ($MAF=0.04$, $OR=15.23$, $[95\%CI]$):

268 15.23 [15.10, 15.36], $P = 9.23 \times 10^{-375}$). While rs137983251-G and rs147525203-C
269 are in complete linkage disequilibrium (LD) with each other ($R^2=1$), rs2296651-A are
270 in less strong LD with rs137983251-G and rs147525203-C ($R^2=0.21$)²⁸.

271

272 **The ICP risk variants at the 14q24.1 locus decrease HBV infection**

273 Notably, *SLC10A1*, also known as *NTCP*, is recognized as a sodium/bile acid
274 cotransporter and has been implicated as the cellular receptor for HBV infection²⁹.
275 Despite this, none of the GWAS studies cataloged in the GWAS catalog,
276 Phenoscanner or PubMed has linked it to TBA or ICP^{24,25}, likely due to its population
277 specificity. To elucidate the function of the East Asian-specific 14q24.1 ICP risk
278 alleles, we scrutinized 246 phenotypes in the Biobank of Japan (BBJ)³⁰ and over 100
279 pregnancy phenotypes in our dataset (see Materials and Methods for URL). We found
280 that lead SNPs of TBA and ICP (rs137983251 and rs147525023) and the rs2296651-A
281 (*p.Ser267Phe*) variant were significantly associated with the traits related to Hepatitis
282 B virus (HBV) infection. In our GWAS of six HBV traits, the 14q24.1 locus stands
283 out as the second most significantly associated locus with HBV infection, exhibiting
284 strong associations with Hepatitis B surface antigen (HBsAg), Hepatitis B e antibody
285 (HBeAb) and Hepatitis B core antibodies (HBcAb) ($P < 5 \times 10^{-8}$) (**Fig. S9**). Stacked
286 LocusZoom plots further confirmed the shared genetic effect between TBA/ICP, and
287 HBV/HBsAg/HBeAb/HBcAb in the 14q24.1 locus (**Fig. S10**). Other traits affected by

288 the 14q24.1 locus include Alanine transaminase level during pregnancy (**Materials**
289 **and Methods** for URL).

290

291 To fine map the potential causal variants contributing to both TBA/ICP and HBV
292 infection, we conducted a colocalization analysis of TBA & ICP and six HBV-related
293 traits on a 1Mbp region (chr14:69-70Mbp) consisting of 1,909 genetic variants
294 (MAF>0.01). We found that TBA and ICP were both colocalized with HBV with at
295 least one variant overlapping in their 95% credible set (PP.H4>0.75 & H4/H3>3) (**Fig.**
296 **2A-B, Fig. S11, Table S7**). Evidence for the strongest colocalization of GWAS
297 signals between TBA and HBV was found for *SLC39A9* (rs138089855, intron variant),
298 and that between ICP and HBV was found for *SCL10A1* (rs2296651, *p.Ser267Phe*,
299 missense variant). The rs138089855-C mutation and rs2296651-A mutation
300 significantly affect immune evasion of HBV infection (*OR* ranging from 0.57 to 0.82,
301 $P < 4.63 \times 10^{-10}$), reducing risks of HBsAg (*OR* ranges from 0.60 to 0.83, $P <$
302 3.72×10^{-5}), HBeAb (*OR* ranges from 0.65 to 0.82, $P < 3.24 \times 10^{-7}$) and HBcAb (*OR*
303 ranges from 0.63 to 0.79, $P < 2.24 \times 10^{-11}$) (**Fig. 2C-D**).

304

305 **The *p.Ser267Phe* mutation of the *SCL10A1* variant became prevalent within the**
306 **last 3,000 years in the areas of East and Southeast Asia**

307 The Geography of Genetic Variants Browser (<https://popgen.uchicago.edu/ggv/>)

308 illustrates that the lead SNP of TBA (rs137983251-G) and ICP (rs147525203-G), as

309 well as the rs138089855-C and missense locus rs2296651-A identified in
310 colocalization analysis, are only present in East and Southeast Asia (**Fig. S12**). To
311 delve further into the historical evolutionary history of ICP genetic loci, we assessed
312 the spatio-temporal frequency differences of rs2296651-A globally and since the
313 Holocene using the Allen Ancient Data Resource (AADR)³¹. In the Holocene era
314 (10,000 BP before now), only one sample with the *p.Ser267Phe* mutation exists in
315 Morocco (**Fig. 3A, Table S8**). In the Neolithic era (10,000~3,000BP), several
316 *p.Ser267Phe* variations appear sporadically, with single samples distributed in Italy,
317 Russia, Spain and California, USA (**Fig. 3B, Table S9**). Notably, until the Historic
318 (<3,000BP), a large number of mutations occurred at this locus, especially within the
319 range of 1,000 to 2,000BP (**Fig. 3C, Table S10**). Currently, the ICP risk mutations of
320 this locus are only distributed in East Asia and Southeast Asia (**Fig. 3D, Table S11**).

321

322 **Natural selection signals in the 14q24.1 locus**

323 The distinctive prevalence of the 14q24.1 locus in different geographical regions may
324 indicate natural selection. To further understand the genetic diversity in the 14q24.1
325 locus, we employed 1KGP high-depth sequencing data for selection analysis. We
326 calculated several metrics based on the site-frequency spectrum in this region for
327 three representative populations: Southern Han Chinese (CHS), Northern Europeans
328 from Utah (CEU), and Yoruba in Ibadan, Nigeria (YRI). We observed a decrease in
329 nucleotide diversity in chr14:69.0-69.2Mbp and around chr14:69.8-69.9 regions in

330 CHS compared to CEU and YRI. Tajima's D and Fay and Wu's F statistics also
331 suggested an excess of high-frequency derived SNPs in these two regions (**Fig. S13**).
332
333 Furthermore, we conducted a selection analysis based on population differentiation
334 and linkage disequilibrium. The chr14:69.0-69.2Mbp region shows the highest
335 locus-specific branch length (LBSL) statistics for CHS compared with the CEU using
336 AFR as the reference panel, indicating a signal of positive selection in East Asia. The
337 results of iHS and the negative $XP-EHH$ values also support that the selection
338 occurred in the CHS population (**Fig. S14**).
339
340 Regarding the high linkage between lead SNPs of TBA and ICP, we explored whether
341 there are differences in haplotype frequencies among different races. We extracted
342 SNPs at high linkage disequilibrium with SNP rs147525203, rs137983251,
343 rs138089855, or rs2296651, resulting in 16 SNPs which were phased into haplotypes.
344 Having examined differences between different races, we found significant
345 differences in haplotypes in East Asians compared to other populations. Of the top 10
346 haplotypes, 4 types (H4, H5, H6, and H9) were almost exclusively found in 10.8% of
347 Asian individuals (**Fig. S15, Table S12**). The origin of these haplotypes was not
348 linked to known archaic ancestry. However, we cannot be ruled out that these
349 haplotypes may have originated from unknown East and Southeast Asian archaic
350 hominins, which are currently underrepresented in human genetic investigations^{32,33,34}.

351

352 **Discussion**

353 Pregnancy constitutes a critical period for human reproduction, and ICP emerges as a
354 high-risk liver disorder during this phase. Characterized by maternal pruritus and
355 elevated serum bile acid concentrations², ICP is associated with an elevated risk of
356 severed pregnancy outcomes, including intrauterine fetal growth restriction, preterm
357 birth, fetal asphyxia, still birth and lower birth weight^{3,4}. Standard clinical practice
358 typically designates pregnancies diagnosed with ICP as high-risk, administering
359 UDCA post-diagnosis, and often inducing labor toward full term. However, recent
360 evidence from an RCT challenges the efficacy of UDCA in reducing adverse perinatal
361 outcomes in women with ICP¹. The high risk and lack of effective treatment of ICP
362 underscores the need for a more comprehensive understanding of the factors leading
363 to ICP. In the present study, we conducted the first-ever GWAS meta-analysis of TBA
364 and ICP traits in East Asians, encompassing 101,023 participants, including 4,703
365 cases and 96,320 controls, with signals verified in two independent Chinese cohorts.
366 We identified eight and three genome-wide significant associated loci for TBA and
367 ICP, respectively, including seven and three novel association loci.

368

369 Of particular interest is the revelation that the most significant 14q24.1 locus
370 contributes to an average odds ratio of 15.23 for ICP in Chinese pregnancies. This is
371 much higher compared to the 1.70 odds ratio for ICP associated with the known

372 *ABCG5* and *ABCB11* loci reported in the European population. The high-risk allele in
373 the 14q24.1 locus, comprising the *SLC39A9* (lead SNP rs137983251), *ERH* (lead SNP
374 rs147525023), and *SLC10A1* (missense variant rs2296651-A, *p.Ser267Phe*) genes, is
375 uniquely present in the East and Southeast Asia and conspicuously absent in other
376 global populations. Comprehensive phenome-wide association scans based on BBJ
377 data and our own dataset revealed a significant association between the ICP-high-risk
378 allele and a protective effect against HBV infection, reflected by a decreased risk of
379 HBV infection, HBsAg, HBcAb, and HBeAb serological positivity. Spatiotemporal
380 and natural selection analyses further suggest that the prevalence of the ICP risk allele
381 dates back within the last 3000 years, putatively due to selection over resistance of
382 HBV infection.

383

384 Currently, Hepatitis B virus (HBV) infection remains a significant public health
385 concern, affecting over 296 million people worldwide chronically infected³⁵. However,
386 little is known about the origin and historical spread of HBV. In 1964, American
387 physician and geneticist Blumberg et al discovered a new antigen in the serum of an
388 Australian Aborigine named Australian antigen (AuAg)³⁶, and subsequently identified
389 it as the surface antigen (HBsAg), marking the first specific indicator of hepatitis B
390 virus (HBV)³⁷. Recent evidence of HBV's historical existence extends to mummies in
391 Korea and Italy from 400 years ago^{38,39}. Moreover, in 2018, the discovery of HBV
392 genomes from ancient DNA derived from human skeletal remains fossilized in the

393 Neolithic period around 7,000 years ago was documented⁴⁰. Our study suggests that a
394 potential HBV epidemic occurred 3,000 years ago in East and Southeast Asia, leading
395 to a balancing or positive selection of the ICP risk allele. This selection resulted in a
396 higher prevalence of ICP observed currently in these regions, shaping a distinct
397 genetic etiology of ICP between East Asians and Europeans.

398

399 What are the medical implications arising from these findings? The first takeaway is
400 that the genetic etiology of ICP differ substantially between Asian and European
401 populations. Clinical practice should take into account the ethnic ancestry of patients
402 for informed clinical decisions, with particular attention to the presence of the
403 14q24.1 ICP risk allele. Secondly, the prevalence of ICP in East and Southeast Asia is
404 an outcome of evolutionary processes. Pregnant individuals carrying the risk alleles
405 exhibited enhanced biological resistance to HBV infection and are likely descendants
406 of survivors from a historical HBV epidemic. Mothers carrying the risk allele need
407 not bear any stigma regarding their infants. Thirdly, evidence on the clinical risk of
408 ICP primarily stems from large-scale cohort-based observational studies⁵, susceptible
409 to confounding by unknown factors. Given the cumulative substantial impact of TBA
410 and ICP risk alleles identified in this study, more refined causal inference regarding
411 the relationship between TBA and ICP and the short-term birth outcomes and
412 long-term offspring health, can be achieved using methods such as Mendelian
413 randomization applied to East-Asian birth cohorts^{41,42}.

414

415 Building upon these discoveries, more precise clinical decisions can be tailored for
416 pregnancies, preventing unnecessary over-treatment. Additionally, novel therapeutics
417 can be developed specifically for high-risk patients based on their genetic origins,
418 compensating for the limited effectiveness of UDCA in reducing adverse outcomes
419 for ICP patients. For example, as HBV vaccinations are mandatorily implemented for
420 newborns in countries like China, it may be worthwhile to explore whether increasing
421 NTCP activity may benefit the ICP patients in clinics while not increasing their risk
422 for HBV infection.

423

424 **Materials and Methods**

425 **Cohort description**

426 The study encompassed 70,608 pregnancies recruited from Longgang District
427 Maternity & Child Healthcare Hospital of Shenzhen City (Longgang cohort) and
428 50,948 pregnancies from Shenzhen Baoan Women's and Children's Hospital (Baoan
429 cohort). These participants engaged in a routine pregnancy screening program in
430 Shenzhen between 2017 and 2022. Pregnancies involving multiple gestations and
431 those lacking TBA level measurements were excluded. Finally, our study comprised
432 101,023 pregnant women who underwent at least one TBA level assessment during
433 gestational weeks 13 to 42.

434

435 To conduct GWAS of TBA and ICP, we integrated NIPT data with clinical phenotypic
436 data (see **Supplementary Methods**). All participants provided written informed
437 consent. The study received approved from the Medical Ethics Committee of the
438 School of Public Health (Shenzhen), Sun Yat-sen University (No. 2022-021),
439 Longgang District Maternity and Child Healthcare Hospital of Shenzhen City
440 (LGFYYXLLL-2022-024), and Shenzhen Baoan Women's and Children's Hospital
441 (LLSC-2021-04-01-10-KS). Data collection was also approved by the Human Genetic
442 Resources Administration of China (HGRAC) (Baoan cohort: [2023]CJ1415,
443 Longgang cohort:[2023]CJ1455).

444

445 **Phenotype definition**

446 The TBA level was defined as the peak level observed for each individual during
447 gestational weeks 13 to 42 after removing outliers (N = 94,360). ICP cases were
448 identified as pregnancies with TBA concentrations $\geq 10\mu\text{mol/L}$ during the same
449 gestational period. In total, 4,703 cases and 96,320 controls for ICP were included in
450 the study.

451

452 We also obtained the hepatitis B antigen and antibody measurements from data of the
453 pregnant screening program. The phenotype of hepatitis B virus (HBV) infection was
454 defined based on hepatitis B antigen and antibody. Detailed information can be found
455 in **Supplementary Methods**.

456

457 **Genome-wide association analysis**

458 We conducted the GWAS analysis using PLINK 2.0⁴³. Covariates such as gestational
459 week, maternal age, and the top ten principal components accounting for population
460 stratification were included in the analysis. The quantitative phenotype (TBA)
461 underwent a rank-based transformation to achieve a normal distribution.

462

463 To integrate results from two cohorts, a meta-analysis was performed using
464 fixed-effect models with inverse-variance weighting, employing METAL software

465 (version 2011-03-25)⁴⁴. Variants with a minor allele frequency (MAF) less than 0.01
466 were excluded. Conditional and joint analysis (GCTA-COJO) was performed using
467 GCTA software^{45,46} to identify independent genome-wide significant signals. A
468 stepwise model selection procedure (--cojo-slet) with a collinearity threshold of 0.2
469 was employed to choose independently associated SNPs, with the reference panel
470 from the Born in Guangzhou Birth cohort (BIGCS)⁴² for the LD structure of the
471 variants. Subsequently, we delineated the range of 500kb upstream and downstream
472 blocks of a significant signal into separate locus, considering the SNP with the lowest
473 *P* value as the lead SNP.

474

475 **Statistic power calculation**

476 All statistical analyses were executed in R (version 4.2.1). Post hoc power
477 calculations were performed to assess the spectrum of effect size (β)/odds ratio (*OR*)
478 and allele frequencies at which associations could be detected at genome-wide
479 significance ($P < 5 \times 10^{-8}$) within a specified number of samples/cases and controls in
480 the meta-analysis. The calculation was performed using the R package “genpwr”⁴⁷
481 (version 1.0.4) using a linear or logistic model under a genetic additive mode.

482

483 **Replication and comparison**

484 For internal replication, we applied stringent criteria to define a locus as replicated,

485 requiring the same beta direction and P values reaching the Bonferroni correction
486 threshold in both the Baoan and Longgang cohorts.

487

488 In the external replication, we replicated genome-wide significant SNPs using two
489 independent study cohorts (Baoan NIPT PLUS cohort and BIGCS cohort). SNPs
490 meeting the following criteria were regarded as replicated: 1) they exhibited a
491 consistent direction of effect for lead SNPs between the discovery and the replication
492 cohorts and 2) they reached Bonferroni-corrected P values or passed a two-sided
493 two-sample t-test. Further details on external replication can be found in

494 **Supplementary methods.**

495

496 Furthermore, we compared the genetic influence of SNPs with a previously published
497 European cohort¹⁶. This comparison involved assessing the direction of genetic effects
498 and Bonferroni-corrected P values of lead SNPs between our meta-analysis results
499 and the European cohort.

500

501 **PheWAS and Colocalization analysis**

502 A PheWAS was conducted using 246 phenotypes from BBJ (<https://pheweb.jp/>) and
503 131 pregnancy phenotypes from the MONN PheWeb established by our research
504 group (<http://47.112.105.165/>). Regions showing evidence of colocalization between
505 the GWAS and GWAS signals were identified utilizing pre-defined thresholds: PP4

506 (posterior probability that there exists a single causal variant common to both traits) \geq
507 0.75 and $PP4/PP3 \geq 3$, employing the R package “coloc” (version 5.1.0.1)⁴⁸. The prior
508 probabilities for SNP association with either of the two traits or with both traits were
509 set to 1×10^{-4} and 1×10^{-5} , the default values, respectively.

510

511 **Geographical frequency distribution analysis**

512 To examine the frequency distribution of identified SNPs across various ancient age
513 groups, we employed ancient DNA data from the compiled 1240K dataset sourced
514 from the Allen Ancient DNA Resource (version 54.1)³¹. The geographical map,
515 supplemented with pie charts, was created using R packages “maps” and “mapplots”
516 to illustrate the geographical frequency distribution.

517

518 **Modern DNA-based selection test**

519 We performed three types of selection tests for modern DNA, encompassing analyses
520 based on site-frequency spectrum (SFS), population differentiation, and haplotype
521 selection to explore signals of positive or balancing selection within East Asia
522 populations. SNPs with minor allele frequencies (MAF) < 0.01 in all five
523 super-populations (AFR, CEU, SAS, EAS and AMR) and genetic variants lacking
524 ancestral information were excluded. Ultimately, 18,221,282 SNPs were used for the
525 natural selection analysis (**Supplementary Methods** for details).

526 **Haplotype analysis**

527 The data used for haplotype analysis corresponds to that employed in the
528 aforementioned natural selection analysis. SNPs with an MAF < 0.05 in all 5
529 super-populations and genetic variants lacking ancestral information were excluded.
530 We extracted SNPs exhibiting high linkage disequilibrium ($R^2 > 0.20$) with
531 rs137983251, rs138089855, rs147525203, or rs2296651 variants, resulting in 16
532 SNPs that were used to construct 31 haplotype types. To further streamline haplotype
533 diversity, the rs79422091 variation was excluded to merge similar haplotypes.
534 Consequently, 16 SNPs were selected to form 25 distinct haplotypes.

535

536 **Abbreviations**

537 AADR, Allen Ancient DNA Resource; BRN, Brunei; CDX, Chinese Dai in
538 Xishuangbanna; CHB, Han Chinese in Beijing; CHS, Southern Han Chinese; CI,
539 confidence interval; COJO, conditional and joint analysis; CQ, Chongqing (China);
540 DE, Germany; DK, Denmark; ES, Spain; FJ, Fujian (China); FSM, Federated States
541 of Micronesia; GWAS, genome-wide association study; GX, Guangxi (China); HA,
542 Henan (China); HBcAb, hepatitis B core antibody; HBeAb, hepatitis B e antibody;
543 HBeAg, hepatitis B e antigen; HBsAb, hepatitis B surface antibody; HBsAg, hepatitis
544 B surface antigen; HBV: hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio;
545 ICP, intrahepatic cholestasis of pregnancy; ID, Indonesia; iHS, integrated Haplotype

546 Score; IS, Iceland; IT, Italy; JPN, Japan; KH, Cambodia; LB, Lebanon; LD, linkage
547 disequilibrium; MA, Morocco; MAF, minor allele frequency; MY, Malaysia; NIPT,
548 non-invasive prenatal testing; OR, odds ratio; PCs, principal components; PH,
549 Philippines; PNG, Papua New Guinea; PP.H, posterior probability for hypothesis; RU,
550 Russia; SFS, site-frequency spectrum; SNP, single nucleotide polymorphism; TBA,
551 total serum bile acids; TWN, Taiwan (China); USA, United States of America; VAN,
552 Vanuatu; VEP, Ensembl Variant Effect Predictor; VN, Vietnam; XJ, Xinjiang (China);
553 XP-EHH, Cross Population Extended Haplotype Homozygosity.
554

555 **Reference**

- 556 1. Chappell, L. C. *et al.* Ursodeoxycholic acid versus placebo in women with
557 intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial.
558 *Lancet* **394**, 849–860 (2019).
- 559 2. Puljic, A. *et al.* The risk of infant and fetal death by each additional week of
560 expectant management in intrahepatic cholestasis of pregnancy by gestational
561 age. *Am. J. Obstet. Gynecol.* **212**, 667.e1-667.e5 (2015).
- 562 3. Glantz, A., Marschall, H. U. & Mattsson, L. Å. Intrahepatic cholestasis of
563 pregnancy: Relationships between bile acid levels and fetal complication rates.
564 *Hepatology* **40**, 467–474 (2004).
- 565 4. Geenes, V. *et al.* Association of severe intrahepatic cholestasis of pregnancy
566 with adverse pregnancy outcomes: A prospective population-based case-control
567 study. *Hepatology* **59**, 1482–1491 (2014).
- 568 5. Ovadia, C. *et al.* Association of adverse perinatal outcomes of intrahepatic
569 cholestasis of pregnancy with biochemical markers: results of aggregate and
570 individual patient data meta-analyses. *Lancet* **393**, 899–909 (2019).
- 571 6. Alsulyman, O. M., Ouzounian, J. G., Ames-Castro, M. & Goodwin, T. M.
572 Intrahepatic cholestasis of pregnancy: perinatal outcome associated with
573 expectant management. *Am. J. Obstet. Gynecol.* **175**, 957–960 (1996).
- 574 7. Sentilhes, L., Verspyck, E., Pia, P. & Marpeau, L. Fetal death in a patient with
575 intrahepatic cholestasis of pregnancy. *Obstet. Gynecol.* **107**, 458–460 (2006).

- 576 8. Ovadia, C. *et al.* Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy:
577 a systematic review and individual participant data meta-analysis. *Lancet*
578 *Gastroenterol. Hepatol.* **6**, 547–558 (2021).
- 579 9. Arrese, M., Macias, R. I. R., Briz, O., Perez, M. J. & Marin, J. J. G. Molecular
580 pathogenesis of intrahepatic cholestasis of pregnancy. *Expert Rev. Mol. Med.*
581 **10**, 1–18 (2008).
- 582 10. Lammert, F., Marschall, H. U., Glantz, A. & Matern, S. Intrahepatic cholestasis
583 of pregnancy: molecular pathogenesis, diagnosis and management. *J. Hepatol.*
584 **33**, 1012–1021 (2000).
- 585 11. Jacquemin, E., Cresteil, D., Manouvrier, S., Boute, O. & Hadchouel, M.
586 Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic
587 cholestasis of pregnancy. *Lancet* **353**, 210–211 (1999).
- 588 12. Schneider, G. *et al.* Linkage between a new splicing site mutation in the MDR3
589 alias ABCB4 gene and intrahepatic cholestasis of pregnancy. *Hepatology* **45**,
590 150–158 (2007).
- 591 13. Dixon, P. H. *et al.* A comprehensive analysis of common genetic variation
592 around six candidate loci for intrahepatic cholestasis of pregnancy. *American*
593 *Journal of Gastroenterology* vol. 109 76–84 at
594 <https://doi.org/10.1038/ajg.2013.406> (2014).

- 595 14. Wasmuth, H. E. *et al.* Intrahepatic cholestasis of pregnancy: The severe form is
596 associated with common variants of the hepatobiliary phospholipid transporter
597 ABCB4 gene. *Gut* **56**, 265–270 (2007).
- 598 15. Chen, R. *et al.* Intrahepatic cholestasis of pregnancy as a clinical manifestation
599 of sodium-taurocholate cotransporting polypeptide deficiency. *Tohoku J. Exp.*
600 *Med.* **248**, 57–61 (2019).
- 601 16. Dixon, P. H. *et al.* GWAS meta-analysis of intrahepatic cholestasis of
602 pregnancy implicates multiple hepatic genes and regulatory elements. *Nat.*
603 *Commun.* **13**, (2022).
- 604 17. Devin D Smith, K. M. R. Intrahepatic Cholestasis of Pregnancy. *Clin. Obstet.*
605 *Gynecol.* **63**, 134–151 (2020).
- 606 18. Lee, R. H., Goodwin, T. M., Greenspoon, J. & Incerpi, M. The prevalence of
607 intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles
608 population. *J. Perinatol. Off. J. Calif. Perinat. Assoc.* **26**, 527–532 (2006).
- 609 19. Reyes, H. Sex hormones and bile acids in intrahepatic cholestasis of pregnancy.
610 *Hepatology* **47**, 376–379 (2008).
- 611 20. Arrese, M. & Reyes, H. Intrahepatic cholestasis of pregnancy: A past and
612 present riddle. *Ann. Hepatol.* **5**, 202–205 (2006).
- 613 21. Gao, X. X. *et al.* Prevalence and risk factors of intrahepatic cholestasis of
614 pregnancy in a Chinese population. *Sci. Rep.* **10**, 16307 (2020).

- 615 22. Liu, S. *et al.* Genomic Analyses from Non-invasive Prenatal Testing Reveal
616 Genetic Associations, Patterns of Viral Infections, and Chinese Population
617 History. *Cell* **175**, 347-359.e14 (2018).
- 618 23. Liu, S. *et al.* Utilizing Non-Invasive Prenatal Test Sequencing Data Resource
619 for Human Genetic Investigation. *bioRxiv* (2023).
- 620 24. Sollis, E. *et al.* The NHGRI-EBI GWAS Catalog: knowledgebase and
621 deposition resource. *Nucleic Acids Res.* **51**, D977–D985 (2023).
- 622 25. Kamat, M. A. *et al.* PhenoScanner V2: An expanded tool for searching human
623 genotype-phenotype associations. *Bioinformatics* **35**, 4851–4853 (2019).
- 624 26. Thul, P. J. & Lindskog, C. The human protein atlas: A spatial map of the human
625 proteome. *Protein Sci.* **27**, 233–244 (2018).
- 626 27. Consortium, Gte. The GTEx Consortium atlas of genetic regulatory effects
627 across human tissues. *Physiol. Behav.* **369**, 1318–1330 (2020).
- 628 28. Machiela, M. J. & Chanock, S. J. LDlink: A web-based application for
629 exploring population-specific haplotype structure and linking correlated alleles
630 of possible functional variants. *Bioinformatics* **31**, 3555–3557 (2015).
- 631 29. Park, J. H. *et al.* Structural insights into the HBV receptor and bile acid
632 transporter NTCP. *Nature* **606**, 1027–1031 (2022).
- 633 30. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human
634 phenotypes. *Nat. Genet.* **53**, 1415–1424 (2021).

- 635 31. Mallick, S. *et al.* The Allen Ancient DNA Resource (AADR): A curated
636 compendium of ancient human genomes. *bioRxiv Prepr. Serv. Biol.* (2023)
637 doi:10.1101/2023.04.06.535797.
- 638 32. Yang, M. A. *et al.* Ancient DNA indicates human population shifts and
639 admixture in northern and southern China. *Science (80-.).* **369**, 282–288
640 (2020).
- 641 33. Wang, C. C. *et al.* Genomic insights into the formation of human populations in
642 East Asia. *Nature* **591**, 413–419 (2021).
- 643 34. Wang, T. *et al.* Human population history at the crossroads of East and
644 Southeast Asia since 11,000 years ago. *Cell* **184**, 3829–3841.e21 (2021).
- 645 35. Kramvis, A. *et al.* A roadmap for serum biomarkers for hepatitis B virus:
646 current status and future outlook. *Nat. Rev. Gastroenterol. Hepatol.* **19**,
647 727–745 (2022).
- 648 36. Blumberg, B. S., Alter, H. J. & Visnich, S. A “New” Antigen in Leukemia Sera.
649 *JAMA* **191**, 541–6 (1965).
- 650 37. Prince, A. M. Relation of Australia and SH antigens. *Lancet* **292**, 462–463
651 (1968).
- 652 38. Kahila Bar-Gal, G. *et al.* Tracing hepatitis B virus to the 16th century in a
653 Korean mummy. *Hepatology* **56**, 1671–80 (2012).
- 654 39. Patterson Ross, Z. *et al.* The paradox of HBV evolution as revealed from a 16th
655 century mummy. *PLoS Pathog.* **14**, e1006750 (2018).

- 656 40. Krause-Kyora, B. *et al.* Neolithic and medieval virus genomes reveal complex
657 evolution of hepatitis B. *Elife* **7**, e36666 (2018).
- 658 41. Qiu, X. *et al.* The Born in Guangzhou Cohort Study (BIGCS). *Eur. J.*
659 *Epidemiol.* **32**, 337–346 (2017).
- 660 42. Huang, S. *et al.* Whole genome sequencing and analysis of 4,053 individuals in
661 trios and mother-infant duos from the Born in Guangzhou Cohort Study.
662 *Research Square* (2022).
- 663 43. Purcell, S. *et al.* PLINK: A tool set for whole-genome association and
664 population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
- 665 44. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: Fast and efficient meta-analysis
666 of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 667 45. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA : A Tool for
668 Genome-wide Complex Trait Analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
- 669 46. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary
670 statistics identifies additional variants influencing complex traits. *Nat. Genet.*
671 **44**, 369–S3 (2012).
- 672 47. Moore, C. M., Jacobso, S. A., Fingerlin, T. E. & Health, N. J. Power and
673 Sample Size Calculations for Genetic Association Studies in the Presence of
674 Genetic Model Mis-Specification. **84**, 256–271 (2019).

675 48. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of

676 Genetic Association Studies Using Summary Statistics. *PLoS Genet.* **10**,

677 e1004383 (2014).

678

679

680 **Figure legends**

681 **Abstract Figure: Genetic basis and evolutionary history of intrahepatic**

682 **cholestasis of pregnancy in East Asia.**

683 TBA: Total bile Acid. ICP: Pregnancy intrahepatic cholestasis. Refer to the main text

684 for the illustration.

685

686 **Fig. 1. Meta-analysis of Genome-wide association study for total bile acid (TBA)**

687 **and intrahepatic cholestasis of pregnancy (ICP).**

688 (A) Manhattan plot for TBA GWAS meta-analysis, encompassing 94,360 samples. (B)

689 Manhattan plot for ICP GWAS meta-analysis, involving 4,703 cases and 96,320

690 controls. Chromosomes are ordered on the x-axis and the $-\log_{10}(P)$ values for the

691 association tests are shown on the y-axis. Horizontal dashed lines delineate the

692 genome-wide significance threshold ($P = 5 \times 10^{-8}$, in grey). Eight and five independent

693 loci achieved genome-wide significance ($P < 5 \times 10^{-8}$) with TBA and ICP, respectively.

694 Labels in black denote known loci and labels in red highlight novel loci.

695

696 **Fig. 2. GWAS-GWAS colocalization of TBA & ICP with HBV and forest plots for**

697 **the shared SNPs with HBV-related traits.**

698 (A) The purple diamond in the plot indicates the colocalized SNP, rs138089855,

699 shared between TBA and HBV. (B) Another SNP, rs2296651, is identified as the
700 colocalized SNP between ICP and HBV. The color coding on the plot signifies
701 the R^2 measure of linkage disequilibrium of the colocalized SNP. The forest plot
702 illustrates the genetic effect of (C) rs138089855-C allele and (D) rs2296651-A allele
703 at 14q24.1 on the meta-analysis for HBV and five HBV antigen & antibody status.
704 The error bars represent the 95% confidence interval of the odds ratio (*OR*).

705

706 **Fig. 3. Temporal and geographical changes of allele frequency of rs2296651.**

707 The geographical frequency distribution of SNP rs2296651 is depicted in (A) the
708 Holocene age (> 10,000BP), (B) the Neolithic age (10,000~3,000BP), (C) the Historic
709 (<3,000BP), and (D) the present-day global populations, utilizing the “1240K” dataset
710 (“Allen Ancient DNA Resource”, version 54.1). The ancestral allele (reference allele)
711 rs2296651-G is represented in orange and the derived allele (alternative allele A, the
712 ICP risk allele) is shown in blue. The color of the pie chart border indicates the
713 detailed archaeological period in the plot in (C) (i.e., red: 0~1,000BP, black:
714 1,000~2,000BP, green: 2,000~3,000BP). Plots (C) and (D) exclusively display
715 populations where rs2296651-A is present. The frequency or quantity of the A allele
716 in different populations is shown in parentheses. Detailed allele frequencies are
717 provided in **Supplementary Table 8-11**.

Cohort

13th to 42nd gestational weeks

Phenotype



TBA
(TBA < 10 μmol/L)

Baoan
(N=38,663)

Longgang
(N=55,697)

ICP
(Diagnosed by if
TBA ≥ 10 μmol/L)

Baoan
(1,931/39,593)


Longgang
(2,772/56,727)

Genetic determinants

GWAS & meta-GWAS


7,300,273 variants (MAF > 0.01)

8 loci identified with TBA and 5 loci with ICP



Phenome-wide colocalization


The 14q24.1 locus was associated with HBV and its related phenotypes



Evolution


Spatio-temporal frequency change

ICP risk allele frequencies throughout world and since Holocene



Natural selection


Natural selection analysis of ICP risk alleles in 14q24.1









Genome sequencing from NIPT



N=101,023

Genotype







A**Holocene(>10000BP)****B****Neolithic(10000-3000BP)****C****Historic(<3000BP)****D****Present**